35 Role of Radiofrequency STRETTA for Recurrent GERD Following Primary Anti-Reflux Surgery and Primary STRETTA Therapy

Abstract Aim This study evaluates the role of STRETTA in patients with recurrent GERD (Gastro Esophageal Refux Disease) symptoms following successful anti-reflux surgery (ARS) and STRETTA. Method A retrospective review was conducted between 2014 and 2024 to identify patients who underwent STRETTA after either primary ARS (OP to STR) or STRETTA (STR to STR). Outcomes were assessed before and after STRETTA using validated RSI (Reflux Symptoms Index) and GERD-HRQL (Health-Related Quality of Life) quality of life (QoL) questionnaires. Results Off the 19 eligible patients, the OP to STR group had 13 patients compared with 6 in STR to STR group. Median time from OP to STRETTA was 8.7 years and 5.5 years in the STR to STR group, p=0.180. OP to STR median follow-up was significantly longer at 5.7 years compared to 0.8 years in the STR to STR group, p=0.008. OP to STR cohort saw a significant reduction in the RSI (Wilcoxon V=84.5, p=0.007) and improvement in QoL (Wilcoxon V= 66, p= 0.004). STR to STR cohort did not show a statistically significant improvement in either RSI (Wilcoxon V=15, p= 0.058) or QoL scores (Wilcoxon V=19, p=0.093). No statistically significant difference noted in PPIs use in either cohort. Conclusions This retrospective small-sample-single-centre study opens the debate about the role of STRETTA in selected recurrent GERD patients following successful primary ARS. Though our limited data showed no statistically significant benefit in RSI and QoL in STR to STR cohort, this is a compelling topic which beseeches for larger robust studies.